Myriad

Myriad Transformed as Data Trove Reveals Significant Historical Uranium Resources at Copper Mountain

Retrieved on: 
星期二, 十月 31, 2023
Neutron, DFN, Comment, Copper Mountain, British Columbia, Technical report, Attention, Union Pacific Railroad, Uranium, Technical, Rush, Projection, CSE, Nature, Human body temperature, ISR, Arrowhead, FSE, Consultant, Myriad, NI, Technical Report Archive & Image Library, Oil, Uranium mining, Tourism

Vancouver, British Columbia--(Newsfile Corp. - October 31, 2023) - MYRIAD URANIUM CORP. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") is pleased to report on historical resource estimates contained in a trove of recently-purchased data relating to the Copper Mountain Uranium Project in Wyoming, USA. This should be considered an interim report because the data review is ongoing. Myriad holds an option to earn up to 75% of the project from Rush Rare Metals Corp. ("Rush"). Currently, the project (the "Copper Mountain Project") comprises 110 mineral claims aggregating 1,911 acres (Figure 1).

Key Points: 
  • The ground considered in these historical estimates is largely within the current claim boundaries of the "Copper Mountain Project", in which Myriad holds an earnable 75% interest.
  • Vancouver, British Columbia--(Newsfile Corp. - October 31, 2023) - MYRIAD URANIUM CORP. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") is pleased to report on historical resource estimates contained in a trove of recently-purchased data relating to the Copper Mountain Uranium Project in Wyoming, USA.
  • The Copper Mountain area contains several known uranium deposits and past-producing uranium mines, including the Arrowhead mine which produced 500,000 lbs U3O8 in the 1950s and 60s.
  • Other estimates include most or all of the known deposits at Copper Mountain, the majority of which are within the Copper Mountain Project.

Global RF Test Equipment Strategic Analysis Report 2023-2030 - OEMs Focus on Leveraging the Strong Demand for Consumer Electronics With Safe & Reliable Product Offerings

Retrieved on: 
星期三, 十一月 1, 2023
Steps, Signal, Others, Importance, Investment, Integration, Projective identification, Defense, Spectrum, Audio system measurements, New Era, Communication, Top, Electronics, Network analyzer (electrical), Medium-altitude long-endurance unmanned aerial vehicle, Business case, Pandemic, RF, Commercial aviation, Factorization of polynomials, Growth, Only Way, Use, Basis, Myriad, Consumer electronics, Unfortunately, We're Not Robots, Television, Pet industry, Video game, Mobile phone, Telecommunications, Opportunity, Automotive industry, Oscilloscope

DUBLIN, Nov. 1, 2023 /PRNewswire/ -- The "RF Test Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 1, 2023 /PRNewswire/ -- The "RF Test Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This report presents a detailed analysis of the RF Test Equipment market.
  • It covers various types of equipment, including RF Test Equipment, Oscilloscopes, Spectrum Analyzers, Signal Generators, Network Analyzers, and more.
  • Various end-uses, such as Consumer Electronics, Telecommunications, Automotive, Aerospace & Defense, and Others, are also covered.

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Retrieved on: 
星期四, 十月 26, 2023
Survival, QGEN, FDA, NYSE, Myriad Genetics, Genetics, SRL Diagnostics, PCR, Health, Cell, MYGN, Circulating tumor DNA, Senior, PMDA, Research fellow, NGS, Partnership, Cancer, MRD, Workflow, Myriad, HRD, GMP, QIAGEN, Patient, Neoplasm, DNA, Vaccine, Medical device

The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.

Key Points: 
  • The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.
  • Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay development expertise and robust commercial infrastructure for clinical sample testing.
  • Our partnership aims to accelerate the advancement of cancer companion diagnostics, making them accessible to pharma partners worldwide,” said Jonathan Arnold, Vice President, Head of Translational Science and Precision Diagnostics at QIAGEN.
  • Myriad has provided testing support for hundreds of clinical trials, has obtained 10 companion diagnostic approvals from the FDA and PMDA, and anticipates that the QIAGEN partnership will drive the expansion of the Myriad portfolio of oncology products.

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Retrieved on: 
星期四, 十月 26, 2023
Survival, QGEN, FDA, NYSE, Myriad Genetics, Genetics, SRL Diagnostics, PCR, Health, SALT, Cell, MYGN, Circulating tumor DNA, Senior, PMDA, Research fellow, NGS, Partnership, Cancer, MRD, Workflow, Myriad, HRD, GMP, QIAGEN, Patient, Neoplasm, DNA, Vaccine, Medical device

The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.

Key Points: 
  • The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.
  • Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay development expertise and robust commercial infrastructure for clinical sample testing.
  • Our partnership aims to accelerate the advancement of cancer companion diagnostics, making them accessible to pharma partners worldwide,” said Jonathan Arnold, Vice President, Head of Translational Science and Precision Diagnostics at QIAGEN.
  • Myriad has provided testing support for hundreds of clinical trials, has obtained 10 companion diagnostic approvals from the FDA and PMDA, and anticipates that the QIAGEN partnership will drive the expansion of the Myriad portfolio of oncology products.

Myriad Acquires Earnable 75% Interest in the Copper Mountain Uranium Project in Wyoming, USA

Retrieved on: 
星期五, 十月 20, 2023
Property, Union Pacific Railroad, Contract management, Rush, News, Option, CSE, South Tyrol Option Agreement, Lease-option, Techno-economic assessment, Canadian Securities Exchange, ISR, Arrowhead, FSE, Agreement, Copper Mountain, Effective date, Letter, Rare-earth element, Security (finance), Share (finance), Myriad

The Property contains a number of other known uranium deposits and there is good potential to discover more.

Key Points: 
  • The Property contains a number of other known uranium deposits and there is good potential to discover more.
  • Rocky Mountain Energy, a subsidiary of Union Pacific, drilled approximately 2,000 boreholes at Copper Mountain between 1969 and 1980.
  • They spent upwards of US$78 million advancing Copper Mountain (2023 dollars), planned a mine for one of its deposits, and built a leach pad.
  • Finally, historical reports suggest the ore at Copper Mountain is leachable and does not require a mill, and it may even be ISR-amenable.

Myriad Uranium Corp. Announces Proposed Transaction Respecting Copper Mountain Project in Wyoming, USA

Retrieved on: 
星期一, 九月 18, 2023
Agreement, Korean Peninsula Energy Development Organization, Arrowhead, Effective date, CSE, Canadian Securities Exchange, Smith Ranch-Highland, Mint, UEC, Option, Specialised Technical Committees of the African Union, Areva, Uranium, ISR, FSE, Research, History, Government, LOI, Niobium, QP, Good, Boxy SVG, Map, Cameco, Pleasure, Energy & Fuels, Uranium mining, Typesetting, Life insurance, Share (finance), Fuller, Property, Rush, Myriad

The Property is comprised of 110 claims in the Copper Mountain district of Wyoming, widely regarded as one of the best uranium exploration jurisdictions in the world.

Key Points: 
  • The Property is comprised of 110 claims in the Copper Mountain district of Wyoming, widely regarded as one of the best uranium exploration jurisdictions in the world.
  • The state of Wyoming and the local community of Riverton near the Copper Mountain Project both have a strong history of supporting uranium mining.
  • Copper Mountain is an outstanding uranium prospect in one of the world's best uranium jurisdictions.
  • Myriad will provide an update respecting the proposed transaction in due course.

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Retrieved on: 
星期二, 九月 19, 2023
DNA, Partnership, Myriad Genetics, HRD, Head, MYGN, TSO, Research, RNA, SALT, Genetics, Patient, Illumina, Inc., Medicine, Genetic testing, IVD, CDX, Gene, Myriad, Vaccine, Illumina

Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency (HRD) testing using the globally distributed Illumina TruSight Oncology 500 (TSO 500) assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants.

Key Points: 
  • Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency (HRD) testing using the globally distributed Illumina TruSight Oncology 500 (TSO 500) assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants.
  • The second milestone involves Myriad’s initiation of its first reproducibility test project to support future regulatory filings for TSO Comp.
  • Myriad now provides support in Illumina’s partnerships with pharmaceutical companies to develop companion diagnostics on TSO Comp.
  • “These key milestones empower Myriad to accelerate the pace of research and scientific innovation to support the advancement of cancer care for patients,” said Paul Bartel, senior vice president of companion diagnostics, Myriad Genetics.

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Retrieved on: 
星期二, 九月 19, 2023
Salt Lake, ClinVar, Myriad Genetics, Registry, Health equity, Woman, MYGN, SALT, Social Security Government Pension Offset, Future, Genetics, Social justice, Patient, Medicine, Biophysical environment, Genetic testing, Climate, ESG, Association for Molecular Pathology v. Myriad Genetics, Inc., Social, Health, Cancer, Environment, Pharmaceutical industry, Management, Myriad

“At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, president and chief executive officer, Myriad Genetics.

Key Points: 
  • “At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, president and chief executive officer, Myriad Genetics.
  • At the end of 2022, women made up 62% of the Myriad workforce and 45% of leadership roles.
  • Since 2019, Myriad has recycled approximately 102 tons of plastic from its Salt Lake City laboratories, including 31.4 tons of plastic during 2022.
  • For more information about Myriad’s ESG efforts, read the 2022 report

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Retrieved on: 
星期一, 九月 18, 2023
Memorial Sloan Kettering Cancer Center, DNA, Circulating tumor DNA, Myriad Genetics, Genomics, Neoplasm, MYGN, Research, SALT, Doctor of Philosophy, MRD, Genetics, Estate (law), Publication, MD, Patient, Medicine, MSK, Genetic testing, Diagnosis, Association for Molecular Pathology v. Myriad Genetics, Inc., Liquid biopsy, Breast cancer, Medical imaging, Myriad

SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer.

Key Points: 
  • SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer.
  • Myriad is working together with Pedram Razavi, MD, PhD, a breast medical oncologist and Director of Liquid Biopsy & Genomics at MSK Global Biomarker Development Program.
  • The MSK research team will investigate the use of MRD testing for patients in two breast cancer cohorts.
  • The second will be focused on the neoadjuvant setting and will assess the association of MRD testing with chemotherapy treatment response.

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Retrieved on: 
星期三, 九月 6, 2023
Myriad Genetics, Culture, MYGN, SALT, Certification, Organization, Genetics, Medicine, Genetic testing, Health, Management, Myriad

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List .

Key Points: 
  • SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List .
  • The highly competitive list is based on the analysis of survey responses from over 208,000 employees from Great Place To Work Certified™ companies in the health care industry.
  • Earlier this year, Myriad achieved the certification , and 86% of Myriad employees said the company is a great place to work – 29 percentage points higher than a typical U.S. company.
  • “This Fortune Best Workplaces in Health Care recognition is a testament to our commitment of inspiring a dynamic and diverse culture, where career development is prioritized, and all teammates have equal opportunity to grow and make a difference in our patients’ lives,” said Shereen Solaiman, chief people officer, Myriad Genetics.